Fig. 1: Analysis of USP35 expression in skin melanoma (SKCM) and its correlation with prognosis of tumor patients.

A Differential expression of USP35 in tumor tissue of various origins and the corresponding adjacent tissues (data from TCGA). B Frequencies and copy number alterations of USP35 mutations across 26 tumor types. Alterations are color-coded as follows: green for missense mutations, red for amplifications, blue for deep deletions, orange for mRNA copy number gain, and gray for multiple alterations. Data were selected from the TCGA Pan-Cancer Atlas via cBioPortal. C The ratio of USP35 gene alteration found in SKCM was 11% (n = 363). Each example is represented as a column. The image includes all USP35 alterations found in the cohort. D Lollipop mutation map showing USP35 mutation sites in the SKCM cohort, which includes the location of 1 truncated mutation and 10 missense mutations in USP35. Lollipop maps are colored relative to the corresponding mutation type: missense mutations are in the green circles, and truncating mutations are in the black circles. Mutations in functional, structural domains of USP35: lollipops of the same height above the line indicate regions with segmental USP35 mutations. These data were extracted from a cohort study of 363 patients in the 2018 TCGA-SKCM Pan-Cancer Atlas (cBioPortal platform). E Differential expression of USP35 mRNA after IgG treatment and anti-PD1 or anti-CTLA4 treatment of malignant melanoma was analyzed using data from the GEO database. F Relationship between USP35 and OS in human cutaneous malignant melanoma from TCGA-SKCM data.